Drug intelligence / Profile preview

AYIFER-XT

Development stage: Unknown
Lead developer: Makshi Healthcare
Modality: Small Molecules
Administration: Oral

Overview

AYIFER-XT is a combination pharmaceutical product marketed by Makshi Healthcare, containing ferrous ascorbate, folic acid, and zinc sulphate. It is primarily used as a hematinic to treat and prevent iron deficiency anemia, particularly in high-demand states such as pregnancy and lactation. Ferrous ascorbate is a synthetic molecule of ascorbic acid and ferrous iron, which offers superior absorption and better gastrointestinal tolerance compared to traditional iron salts. Folic acid is essential for DNA synthesis and the prevention of neural tube defects, while zinc acts as a vital cofactor for various enzymes involved in cellular metabolism and immune function.

Brand names: AYIFER-XT
Other names: AYIFER-XT-Makshi

Targets

SLC11A2 (DMT1)DHFR (Dihydrofolate reductase)SLC39A4 (Zinc transporter ZIP4)

Beyond the preview

Go deeper on AYIFER-XT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AYIFER-XT.

Explore the full profile